

Cardiosol

SUPPLEMENT FACTS

Serving size: Three vegetable capsules

Servings per container: 30

	Amount per serving	% Daily value
Guggul resin extract (standardized to 10% guggulsterones)	1000 mg	**
L-carnitine	800 mg	**
Coenzyme Q10 (from Japan)	150 mg	**
Policosanol (from sugarcane wax)	20 mg	**

** daily value not established

Other ingredients: cellulose, silicon dioxide, vegetable stearate.

[product label]

Cardiosol

Helps lower cholesterol levels and maintain cardiovascular health

Cardiosol is nutraOrigin's unique all-natural formula designed to help lower cholesterol levels and maintain the overall health of your heart. **Policosanol** is an exciting natural compound purified from sugarcane that delivers powerful support for overall cardiovascular health. Numerous studies conclude that it may lower blood cholesterol and triglyceride levels. **Guggul resin** has been used in traditional Hindu medicine for more than 2,000 years. Scientists have discovered that this tree extract may reduce LDL (bad cholesterol) levels, strengthen arteries, and promote circulatory health. **L-carnitine** can improve the body's disposal of glucose by converting fatty acids into energy. This natural nutrient may provide overall heart protection by making fatty acids available for heart muscle tissue. **Coenzyme Q10** also may sustain heart health by converting food to energy, promoting healthy circulation through myocardial tissues.

Together, the synergy of these ingredients makes **Cardiosol** a heart-smart agent for your health and strength.

[product web page / front page]

Cardiosol is a powerful, innovative formula for superior cardiovascular health, aimed at lowering and maintaining cholesterol and triglyceride levels, as well as blood pressure. **Cardiosol** benefits your overall circulatory health and aptitude for physical activity and performance. Incorporate **Cardiosol** into your daily routine for effective heart-health benefits.

Cardiosol:

- Aids the regulation of blood lipids.
- Lowers triglycerides.
- Lowers blood pressure.
- Increases HDL (good cholesterol) levels.
- Decreases LDL (bad cholesterol) levels.
- Reduces arteriosclerotic plaque in blood vessels.
- Supports overall circulatory health.
- Protects the heart from free radicals.
- Improves heart muscle tissue.
- Decreases shortness of breath and heart palpitations.
- Works fast, and is proven effective.

Why Cardiosol is Superior

- Only the best, most natural, scientifically proven ingredients used
- No ingredients with unproven effects
- Pharmaceutical grade and quality
- Wide spectrum of effective compounds, as opposed to lesser formulas with just a few ingredients
- Guaranteed pure and potent
- Ingredients fully evaluated and approved for safety and satisfaction (see certificate of analysis)

- Higher dosages and potency than most brands
- Quality backed by independent inspection
- Manufactured and packaged in facilities with the Good Manufacturing Practices (GMP) clean bill of health certification, which assures the highest level of quality.

[product web page / how-it-works page]

How Cardiosol Works

Cardiosol is developed scientifically, containing only proven, effective, all-natural ingredients, each of which has undergone extensive research for your safety and satisfaction. The ingredients described below will give you a better understanding of how this product works.

Policosanol

The form of policosanol employed by nutraOrigin, derived from sugar cane wax, has proven superior to the rice-based policosanol found in competitive products. Used mainly for treating elevations in blood cholesterol and lipids (fats), policosanol works by slowing the synthesis of cholesterol in the liver and by hastening the breakdown of low-density lipoprotein (LDL or bad cholesterol). (1, 2) In several studies, it decreased LDL by 11 to 31 percent and raised high-density lipoprotein (HDL or good cholesterol) by seven to nine percent. (3–5) Policosanol’s effect on improving cholesterol has been compared to that of prescription pharmaceuticals, and determined to be just as effective. (6, 7)

Guggul Resin Extract

Guggul (*Commiphora mukul*) is a botanical with an established tradition in Ayurvedic medicine, used effectively as a lipid-lowering agent. It has been shown to lower LDL levels while raising HDL levels. Lowering overall cholesterol may lead to reduced risk of atherosclerosis and related cardiovascular diseases. (24) Guggul also may lower

triglycerides and very-low-density lipoprotein (VLDL). (8) It assists the heart and cardiovascular system by preventing platelet aggregation. (9)

L-Carnitine

Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine. (11) In testing, L-carnitine has promoted improvements in the heart muscle (18) and has shown promise in patients with irregular heartbeat, heart muscle inflammation (cardiomyopathy) and angina. (19–21) Further research suggests that L-carnitine can lower LDL cholesterol while raising HDL cholesterol. (22)

Coenzyme Q₁₀

Coenzyme Q₁₀ (Japan), also known as ubiquinone, ubidecarenone, coenzyme Q, CoQ₁₀, CoQ, Q₁₀, or Q, is a benzoquinone. This vitamin-like substance is present in most human cells and is responsible for the production of the body's own energy. Individuals who had suffered heart failure who took CoQ₁₀ experienced an increase in exercise capacity, performance, and recovery (13, 17) Patients with symptoms of high blood pressure, mitral valve prolapse, and angina have benefited by the use of coenzyme Q₁₀, (14) which also increases HDL levels. (15) Following a heart attack, a reduction in cardiac events, including the development of atherosclerosis, has been shown. (16) In one study, CoQ₁₀ has yielded improvements in common symptoms of congestive heart failure, such as cyanosis, edema, shortness of breath, heart palpitations, sweating, insomnia, vertigo, and arrhythmias. (12)

Bibliography

1. Menendez R., Arruzabala L., Mas R., et al. "Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet." *Br J Nutr* (1997) 77: 923–32.
2. Menendez R., Fernandez S.I., Del Rio A., et al. "Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts." *Biol Res* (1994) 27: 199–203.

3. Canetti M., Moreira M., Mas R., et al. "A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia." *Int J Clin Pharmacol Res* (1995) 15: 159–65.
4. Pons P., Rodriguez M., Robaina C., et al. "Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment." *Int J Clin Pharmacol Res* (1994) 14: 27–33.
5. Torres O., Agramonte A.J., Illnait J., et al. "Treatment of hypercholesterolemia in NIDDM with policosanol." *Diabetes Care* (1995) 18: 393–7.
6. Fernandez J.C., Mas R., Castano G., et al. "Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women." *Clin Drug Invest* (2001) 21: 103–113.
7. Ortensi G., Gladstein J., Valli H., Tesone P.A. "Comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia." *Curr Ther Res* (1997) 58: 390–401.
8. Urizar N.Z., Moore D.D. "Guggulipid: a natural cholesterol-lowering agent." *Annu Rev Nut* (2003) 23: 303–313.
9. "Guggul." PDRHealth www.pdrhealth.com (2005) February.
10. Hurot J.M., Cucherat M., Haugh M., Fouque D. "Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review." *J Am Soc Nephrol* (2002) 13: 708–14.
11. Steiber A., Kerner J., Hoppel C. "Carnitine: a nutritional, biosynthetic, and functional perspective." *Mol. Aspects Med.* (2004) 25 (5–6): 455–73.
12. Baggio E., Gandini R., Plancher A.C., Passeri M., Carmosino G. "Italian multi-center study on the safety and efficacy of Coenzyme Q10 as an adjunctive therapy in heart failure. Coenzyme Q10 Surveillance Investigators." *Mol Aspects Med* (1994) 15 (Suppl): S287–294.
13. Hofman-Bang C., Rehqvist N., Swedberg K., Wiklund I., Astrom H. "Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The CoQ10 Study Group." *J Card Fail* (1995) Mar; 1(2): 101–107.
14. Langsjoen H., Langsjoen P., Willis R., Folkers K. "Usefulness of coenzyme Q10 in clinical cardiology: a long-term study." *Mol Aspects Med* (1994) 15 (Suppl): S165–175.
15. Singh R.B. et al. "Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction." *Mol Cell Biochem* (2003) Apr; 246(1–2): 75–82.
16. Burke B.E., Neuenschwander R., Olson R.D. "Randomized, double blind placebo controlled trial of coenzyme Q10 in isolated systolic hypertension." *South Med J* (2001) Nov; 94(11): 1112–1117.
17. Ylikoski T., Piirainen J., Hanninen O., Penttinen J. "The effect of coenzyme Q10 on the exercise performance of cross-country skiers." *Mol Aspects Med* (1997) 18 (Suppl): S283–290.
18. Rebouche, C.J. et al. "Carnitine metabolism and deficiency syndrome" *Mayo Clinic Proc* (1983) 58: 533–540.

19. Cherchi A., et al. "Effects of L-carnitine on exercise tolerance in chronic stable angina: A multicenter, double-blind, randomized, placebo controlled crossover study." *Int J Clin Pharmacol Ther Toxicol* (1985) Oct; 23(10): 569–72.
20. Mondillo S., et al. "Therapy of arrhythmia induced by myocardial ischemia. association of l-carnitine, propafenone and mexiletine." *Clin Ter* (1995) Dec; 146(12): 769–74.
21. Winter S., et al. "The role of l-carnitine in pediatric cardiomyopathy." *J Child Neurol* (1995) Nov; 10 (Suppl2): S45–51.
22. Pola P., et al. "statistical evaluation of long-term L-carnitine therapy in hyperlipoproteinemias." *Drugs Exptl Clin Res* (1983) 9: 925–34.
23. Brevetti G., et al. "superiority of l-propionylcarnitine vs. L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study." *Eur Heart J* (1992) Feb; 13(2): 251–55.
24. Singh V., et al. "stimulation of low density lipoprotein receptor activity in liver membrane of guggulsterone treated rats." *Pharmacol Res* (1990) 22(1): 37–44.
25. Baldwa V.S., et al. "Effects of *Commiphora mukul* (guggul) in experimentally induced hyperlipidemia and atherosclerosis. *J Assoc Physicians India* (1981) 29(1): 13–17.
26. Satyavati G.V., et al. "Guggulipid: A promising hypolipidemic agent from gum guggul (*Commiphora Wightii*)." *Econ Med Plant Res* (1991) 5: 48–82.